BCR-ABL Gene Fusion Qualitative Test at Lahore PCR Lab

BCR-ABL Gene Fusion (Qualitative) at Lahore PCR Lab

The BCR-ABL Gene Fusion (Qualitative) test is a highly specialized molecular diagnostic assay designed to detect the presence of the BCR-ABL1 chimeric fusion gene. This abnormal gene is the hallmark of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22, designated as t(9;22)(q34.1;q11.2). At Lahore PCR Lab, located in Lahore, Pakistan, this test is performed utilizing advanced Reverse Transcription-Polymerase Chain Reaction (RT-PCR) technology to provide patients and oncologists with definitive diagnostic insights. The identification of this fusion gene is critical for the diagnosis, classification, and management of specific hematological malignancies, primarily Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Under normal physiological conditions, the ABL1 gene on chromosome 9 encodes a tyrosine kinase enzyme involved in cell growth and differentiation, while the BCR gene on chromosome 22 encodes a protein with GTPase-activating and kinase activities. When these two genes fuse, they produce a chimeric BCR-ABL1 protein with constitutive, unregulated tyrosine kinase activity. This aberrant protein continuously signals the bone marrow to produce excessive, dysfunctional white blood cells, leading to leukemia. By detecting the presence of BCR-ABL1 messenger RNA (mRNA) transcripts, the qualitative PCR test confirms the molecular basis of the disease, allowing hematologists to initiate targeted therapies such as Tyrosine Kinase Inhibitors (TKIs).

Lahore PCR Lab employs state-of-the-art molecular biology equipment and stringent quality control protocols to perform this assay. The qualitative nature of this test means it provides a clear “Detected” or “Not Detected” result, establishing a baseline for patients suspected of having leukemia. It evaluates the peripheral blood or bone marrow aspirate at a cellular level, offering unparalleled diagnostic sensitivity compared to conventional cytogenetics. Understanding the molecular profile of leukemia is the cornerstone of modern precision oncology, and this test serves as an indispensable tool in the diagnostic pathway.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular results. Patients undergoing the BCR-ABL Gene Fusion (Qualitative) test at Lahore PCR Lab should observe the following guidelines:

• No Fasting Required: There is no need to fast before this test. Patients can consume food and liquids normally unless instructed otherwise for concurrent tests.
• Medical History Documentation: Patients must provide a complete clinical history, including any current or past treatments with Tyrosine Kinase Inhibitors (TKIs) like imatinib, nilotinib, or dasatinib, as well as history of bone marrow transplantation.
• Medication Reporting: Inform the laboratory staff and your physician of all prescription and over-the-counter medications, particularly blood thinners, which may affect the collection site.
• Hydration: Staying well-hydrated is recommended to facilitate easier venous access during blood collection.
• Consent and Referral: Ensure you bring a valid doctor’s prescription and any previous hematology reports (such as a Complete Blood Count or bone marrow biopsy report) to the lab.

During the Procedure

The procedure for the BCR-ABL Gene Fusion test involves the collection of either a peripheral blood sample or a bone marrow aspirate, depending on the clinician’s recommendation. The process is conducted with the highest standards of clinical safety and hygiene:

• Specimen Collection (Peripheral Blood): A phlebotomist will locate a suitable vein in your arm, cleanse the area with an antiseptic solution, and insert a sterile needle to draw blood into an EDTA (lavender top) tube. This is the most common and minimally invasive method.
• Specimen Collection (Bone Marrow): If a bone marrow aspirate is required, a qualified hematologist or oncologist will perform the procedure under local anesthesia in a clinical setting, extracting a small amount of liquid bone marrow from the hip bone.
• Sample Transport and Stability: Once collected, the sample is immediately labeled and transported to the molecular diagnostics division of Lahore PCR Lab under controlled temperature conditions to prevent RNA degradation.
• Molecular Processing: In the laboratory, specialized technologists extract total RNA from the white blood cells. This RNA is reverse-transcribed into complementary DNA (cDNA), which is then amplified using specific primers targeting the BCR-ABL1 fusion transcripts via RT-PCR.
• Safety and Comfort: The blood draw takes less than five minutes and involves minimal discomfort, similar to a brief pinch. Bone marrow collection takes longer and is performed with appropriate pain management.

When is a BCR-ABL Gene Fusion (Qualitative) Performed?

Chronic Myeloid Leukemia (CML) Diagnosis

The primary clinical indication for ordering a BCR-ABL qualitative test is the suspected diagnosis of Chronic Myeloid Leukemia. Clinicians suspect CML when a patient presents with persistent, unexplained leukocytosis, often accompanied by left-shifted myeloid maturation in the peripheral blood. The qualitative detection of the BCR-ABL1 fusion gene confirms the diagnosis of CML in approximately 95% of cases, distinguishing it from other myeloproliferative neoplasms or reactive leukocytosis (leukemoid reactions).

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

In patients diagnosed with Acute Lymphoblastic Leukemia, determining the presence of the BCR-ABL1 gene fusion is crucial for risk stratification and treatment planning. Approximately 20% to 30% of adult ALL cases and a smaller percentage of pediatric cases are Philadelphia chromosome-positive. Detecting this fusion gene classifies the leukemia into a high-risk category, indicating the immediate need to incorporate tyrosine kinase inhibitors into the chemotherapy regimen to improve survival outcomes.

Monitoring Therapeutic Response to Tyrosine Kinase Inhibitors (TKIs)

While quantitative PCR is the standard for monitoring log reductions in transcript levels, the qualitative BCR-ABL test is performed at critical clinical milestones to confirm complete molecular response (CMR). When a patient’s qualitative test returns a “Not Detected” result, it indicates that the level of the fusion transcript has fallen below the detection limit of the assay, signifying an excellent therapeutic response to TKI therapy.

Evaluation of Unexplained Leukocytosis and Splenomegaly

Physicians frequently request this test when investigating patients who present with a combination of unexplained, massive leukocytosis (high white blood cell count) and splenomegaly (enlarged spleen). These clinical signs are classic hallmarks of myeloproliferative disorders. Confirming the presence of the BCR-ABL gene fusion helps rule out other causes of splenomegaly and guides the physician directly to a targeted oncological intervention.

Detection of Minimal Residual Disease (MRD) and Relapse

For patients in clinical remission following chemotherapy, TKI therapy, or an allogeneic stem cell transplant, the qualitative BCR-ABL test is used to screen for minimal residual disease or early molecular relapse. A shift from a “Not Detected” status to a “Detected” status is a highly sensitive indicator of disease recurrence, often preceding hematological or clinical relapse by several months, allowing for early therapeutic adjustment.

What Does a BCR-ABL Gene Fusion (Qualitative) Detect?

The BCR-ABL Gene Fusion (Qualitative) assay at Lahore PCR Lab is designed to detect several molecular and clinical parameters associated with the t(9;22) translocation:

• Presence of the BCR-ABL1 chimeric fusion gene transcript in the patient’s specimen.
• Absence of the BCR-ABL1 fusion transcript, ruling out Philadelphia chromosome-positive malignancies.
• The major breakpoint cluster region (M-bcr) transcript, resulting in the p210 fusion protein (common in CML).
• The minor breakpoint cluster region (m-bcr) transcript, resulting in the p190 fusion protein (common in Ph+ ALL).
• The micro breakpoint cluster region (μ-bcr) transcript, resulting in the p230 fusion protein (associated with chronic neutrophilic leukemia).
• The e13a2 (b2a2) junction variant of the p210 fusion transcript.
• The e14a2 (b3a2) junction variant of the p210 fusion transcript.
• The e1a2 junction variant of the p190 fusion transcript, indicating lymphoblast-specific oncogene activation.
• Atypical fusion transcripts (such as e19a2 or e1a3) that may require specialized monitoring.
• Verification of sample adequacy through the amplification of an internal control gene (such as ABL1 or GUSB).
• Presence of the Philadelphia chromosome translocation at the molecular level, even when cytogenetic karyotyping is unsuccessful.
• Early molecular signs of disease recurrence in post-transplant patients.
• Molecular confirmation of complete hematological remission.
• The underlying genetic driver of unexplained, extreme thrombocytosis.
• The genetic cause of persistent neutrophilic leukocytosis.
• The presence of clonal hematopoiesis driven by the BCR-ABL1 oncogene.
• Eligibility of the patient for targeted Tyrosine Kinase Inhibitor (TKI) therapies.
• High-risk genetic status in pediatric and adult acute leukemia patients.
• Baseline molecular status prior to the initiation of cytoreductive therapy.
• The molecular differentiation between CML and atypical chronic myelomonocytic leukemia (CMML).
• The molecular differentiation between CML and essential thrombocythemia.
• The molecular differentiation between CML and polycythemia vera.
• The presence of residual leukemic clones in patients undergoing clinical trials.
• The quality and integrity of the extracted RNA from the patient’s blood or marrow sample.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for oncological test results can be an anxious time for patients and their families. Because molecular testing involves complex steps—including RNA extraction, reverse transcription, amplification, and rigorous quality control verification—the turnaround time for the BCR-ABL Gene Fusion (Qualitative) test is typically within 3 to 5 working days. This timeline ensures that every sample is processed with the highest level of precision and that all positive results are double-checked for clinical accuracy.

Once the report is finalized by our consultant molecular pathologists, patients and referring physicians can access the results conveniently. Lahore PCR Lab offers digital report access through an online portal on our official website. Patients receive an SMS notification containing a secure link and login credentials as soon as the report is ready. Physical copies of the report can also be collected directly from our main diagnostic center in Lahore or delivered via our courier service.

BCR-ABL Gene Fusion Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 Fusion Transcript	Not Detected	Detected (indicates presence of t(9;22) translocation)
Internal Control Gene (ABL1/GUSB)	Adequately Amplified	Not Amplified (indicates degraded RNA or PCR inhibition)
Major Transcript (p210)	Not Detected	Detected (highly associated with Chronic Myeloid Leukemia)
Minor Transcript (p190)	Not Detected	Detected (associated with Ph+ Acute Lymphoblastic Leukemia)
Micro Transcript (p230)	Not Detected	Detected (associated with Chronic Neutrophilic Leukemia)
Specimen Quality / RNA Integrity	High Quality (Acceptable for PCR)	Poor Quality (Requires fresh sample collection)
Clinical Interpretation	No molecular evidence of Philadelphia Chromosome	Molecular confirmation of Philadelphia-positive leukemia

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for BCR-ABL Gene Fusion (Qualitative)?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified pathologists and molecular biologists with extensive experience in oncological diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process, from sample collection to reporting.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international standards of quality control, ensuring highly reproducible and accurate molecular results.
• Professional Reporting: Our reports are detailed, structured, and easy for clinical oncologists to interpret, facilitating rapid treatment decisions.
• Modern Diagnostic Approach: We utilize advanced RT-PCR platforms and high-grade reagents to minimize the risk of false-positive or false-negative results.
• Comfortable Environment: Our diagnostic center in Lahore is designed to provide a clean, hygienic, and stress-free environment for all patients.
• Convenient Location: Located centrally in Lahore, our laboratory is easily accessible for patients traveling from different parts of the city and surrounding areas.
• Commitment to Accurate Diagnosis: We understand the critical nature of leukemia diagnostics and are committed to delivering timely, precise molecular insights to guide life-saving therapies.